Valiant Laboratories IPO
Valiant Laboratories is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company that was founded in 2021 and specialises in the production of paracetamol. Drugs in bulk or API are used as raw materials to create formulations or finished dosage forms.
The manufacturing facility for Valiant Laboratories is situated in Palghar, Maharashtra, India, and spans a total area of land totaling roughly 2,000 square metres. It has a total installed capacity of 9,000 MT per year.
The revenue from sales outside of India contributed 0.39%, 0.60%, and 0.33%, respectively, of the total revenue from operations for the financial years ended 31 March 2023, 2022, and 2021. Between FY 2017 and FY 2023, the revenue from operations increased at a CAGR of 23.90%.
Valiant Laboratories IPO Details
| Signature Global IPO Details | ||
|---|---|---|
|
Valiant Laboratories IPO Dates |
27 Sep – 3 Oct 2023 |
|
|
Valiant Laboratories IPO Price |
INR 133 – 140 per share |
|
|
Fresh issue |
10,890,000 shares
INR 144.84 – 152.46 crore
|
|
|
Offer For Sale |
NIL |
|
|
Total IPO Size |
11,556,000 shares
INR 144.84 – 152.46 crore
|
|
|
Minimum bid (size) |
105 shares
INR 14,700
|
|
|
Face Value |
INR 10 per share |
|
|
Retail Allocation |
35% |
|
|
Listing On |
BSE, NSE |
|
Valiant Laboratories Financial Performance
| Signature Global Financial Performance | |||
|---|---|---|---|
|
|
FY21 |
FY22 |
FY23 |
|
Revenue |
82.38 |
209.14 |
333.91 |
|
Expenses |
72.04 |
179.73 |
300.64 |
|
Net income |
4.75 |
22.59 |
29.03 |
|
Margin (%) |
5.77 |
10.80 |
8.69 |
Figures in INR Crore unless specified otherwise